Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 425876, 5 pages
http://dx.doi.org/10.1155/2015/425876
Research Article

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma

1Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, Japan
2Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama 2630, Japan

Received 29 November 2014; Revised 29 May 2015; Accepted 1 June 2015

Academic Editor: Antoni Castells

Copyright © 2015 Takayuki Ando et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. T. Bosman, F. Carbeuri, R. H. Hruban, and N. D. Theise, WHO Classification of Tumors of the Digestive System, WHO Press, Geneva, Switzerland, 4th edition, 2010.
  2. E. Galanis, S. Frytak, and R. V. Lloyd, “Extrapulmonary small cell carcinoma,” Cancer, vol. 79, no. 9, pp. 1729–1736, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. E. Walenkamp, G. S. Sonke, and D. T. Sleijfer, “Clinical and therapeutic aspects of extrapulmonary small cell carcinoma,” Cancer Treatment Reviews, vol. 35, no. 3, pp. 228–236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Fazio, F. Spada, and M. Giovannini, “Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view,” Cancer Treatment Reviews, vol. 39, no. 3, pp. 270–274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. H. Kulke, B. Wu, D. P. Ryan et al., “A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors,” Digestive Diseases and Sciences, vol. 51, no. 6, pp. 1033–1038, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Jin, T. Wang, X. Chen et al., “Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma,” Onkologie, vol. 34, no. 7, pp. 378–381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Sorbye, J. Strosberg, E. Baudin, D. S. Klimstra, and J. C. Yao, “Gastroenteropancreatic high-grade neuroendocrine carcinoma,” Cancer, vol. 120, no. 18, pp. 2814–2823, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Welin, H. Sorbye, S. Sebjornsen, S. Knappskog, C. Busch, and K. Öberg, “Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy,” Cancer, vol. 117, no. 20, pp. 4617–4622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Onoda, N. Masuda, T. Seto et al., “Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301,” Journal of Clinical Oncology, vol. 24, no. 34, pp. 5448–5453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Ettinger, R. Jotte, P. Lorigan et al., “Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer,” Journal of Clinical Oncology, vol. 28, no. 15, pp. 2598–2603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Inoue, S. Sugawara, K. Yamazaki et al., “Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: north Japan lung cancer study group trial 0402,” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5401–5406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Asayama, N. Fuse, T. Yoshino et al., “Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 5, pp. 1325–1330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Murakami, N. Yamamoto, T. Shibata et al., “A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901),” Lung Cancer, vol. 84, no. 1, pp. 67–72, 2014. View at Publisher · View at Google Scholar
  14. Y. Sugimoto, S. Tsukahara, T. Oh-Hara, T. Isoe, and T. Tsuruo, “Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody,” Cancer Research, vol. 50, no. 21, pp. 6925–6930, 1990. View at Google Scholar · View at Scopus
  15. Y. Sugimoto, S. Tsukahara, T. Oh-hara, L. F. Liu, and T. Tsuruo, “Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines,” Cancer Research, vol. 50, no. 24, pp. 7962–7965, 1990. View at Google Scholar · View at Scopus
  16. K. B. Tan, M. R. Mattern, W.-K. Eng, F. L. McCabe, and R. K. Johnson, “Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors,” Journal of the National Cancer Institute, vol. 81, no. 22, pp. 1732–1735, 1989. View at Publisher · View at Google Scholar · View at Scopus
  17. F.-L. Vélayoudom-Céphise, P. Duvillard, L. Foucan et al., “Are G3 ENETS neuroendocrine neoplasms heterogeneous?” Endocrine-Related Cancer, vol. 20, no. 5, pp. 649–657, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Chan, K. Stuart, C. C. Earle et al., “Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors,” Journal of Clinical Oncology, vol. 30, no. 24, pp. 2963–2968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Strosberg, “Advances in the treatment of pancreatic neuroendocrine tumors (pNETS),” Gastrointestinal Cancer Research, vol. 6, no. 4, pp. S10–S12, 2013. View at Google Scholar · View at Scopus